Adjuvant
Product Details
| Alternative Name: | MPL-A from Salmonella minnesota R595 (Re) |
| |
| Source: | Isolated from Salmonella minnesota R595 (Re mutant). Prepared by acid hydrolysis from purified Salmonella minnesota R595 (Re) LPS (isolated by a modification of the PCP extraction method), converted to the uniform salt form and dissolved in sterile pyrogen-free double distilled water. |
| |
| Concentration: | 1mg/ml |
| |
| Formulation: | Liquid. Sterile, ready-to-use solution in pyrogen-free double distilled water. |
| |
| Purity: | ≥99.9% (regarding protein or DNA contaminants; KDO not detectable) |
| |
| Activity: | Activates Toll-like receptor (TLR) 4. Does not activate TLR2 as determined with splenocytes and macrophages from TLR4 deficient mice. Exhibits reduced endotoxic and pyrogenic activity compared to lipid A and LPS. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Handling: | Keep sterile. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
MPL Adjuvant Contains Competitive Antagonists of Human TLR4: Y.Q. Wang, et al.; Front. Immunol.
11, 577823 (2020),
Abstract;
Full Text
Specific features of human monocytes activation by monophosphoryl lipid A: R. Chentouh, et al.; Sci. Rep.
8, 7096 (2018),
Abstract;
Full Text
CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS: T. Regen, et al.; Brain Behav. Immun.
25, 957 (2011),
Abstract;
Isolation and purification of R-form lipopolysaccharides: C. Galanos & O. Luderitz; Meth. Carbohydr. Chem. 9, 11 (1993),
Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms: C. Galanos & O. Luderitz; Eur. J. Biochem.
54, 603 (1975),
Abstract;
A new method for the extraction of R lipopolysaccharides: C. Galanos, et al.; Eur. J. Biochem.
9, 245 (1969),
Abstract;
Related Products
